Papa 2A Lapaʻau ʻana i ka maʻi maʻi ʻāʻī 2026: ʻIkepili ELCC hou ma ka lāʻau lapaʻau Neo-Adjuvant 

Mākaʻikaʻi ʻana o ka maʻi maʻi ʻāʻī o ka pae 2A i ka makahiki 2026, ua hoʻololi nui ʻia, e neʻe ana mai ka ʻoki wale ʻana i nā hoʻolālā multimodal e hoʻopili ana i ka neo-adjuvant therapy. Hoʻoikaika nā alakaʻi o kēia manawa i ka hoʻohui ʻana i ka immunotherapy a me ka chemotherapy ma mua o ka ʻoki ʻana e hoʻomaikaʻi i nā helu pane piha pathological (pCR) a me ke ola lōʻihi. Hōʻike ʻia nā ʻikepili hou mai ka 2026 European Lung Cancer Congress (ELCC) i nā regimens hou, e komo pū ana me nā mea hoʻopaneʻe ʻelua-checkpoint a me ka radiotherapy immunogenic, e wehewehe hou ana i nā hopena no ka maʻi maʻi maʻi maʻi ʻaʻole liʻiliʻi liʻiliʻi (NSCLC).

Ka hoʻomaopopo ʻana i ka Papa 2A ʻAʻole i ka maʻi maʻi maʻi ʻāʻī

Hōʻike ka pae 2A NSCLC i kahi hui koʻikoʻi i ka mālama ʻana i ka maʻi maʻi maʻi maʻi kahi i hoʻopaʻa ʻia ai ka maʻi ʻaʻai akā e lawe ana i kahi maʻi micrometastatic. ʻO ka mōʻaukala, ʻo ka ʻoki ʻoki ʻana koke i ke kūlana o ka mālama. Eia nō naʻe, ʻike ka oncology hou i ka mālama ʻia ʻana o ka systemic therapy ma mua o ke kaʻina hiki ke hoʻopau koke i ka maʻi ʻike ʻole ʻia.

ʻO ka wehewehe ʻana o ka Papa 2A e pili ana i nā ʻōpū ʻoi aku ka nui ma mua o 3 knm akā ʻaʻole i ʻoi aku ma mua o 4 knm me ka ʻole o ke komo ʻana o ka lymph node, a i ʻole nā maʻi ʻuʻuku liʻiliʻi me nā hōʻeha kūloko. ʻO ka hoʻonohonoho pololei ka mea nui, no ka mea e kuhikuhi ana i ka pono no nā protocol neo-adjuvant.

• Nui ka nui: ʻO ka maʻamau ma waena o 3 knm a me 4 knm no ka hoʻohālikelike T2a N0 M0.
• Kūlana Lymph Node: ʻO ka maʻamau, ʻaʻohe metastasis lymph node regional (N0), ʻoiai he mea hopohopo ke komo ʻana i ka microscopic.
• Hoʻoponopono hou ʻia: Manaʻo ʻia nā poʻe maʻi he poʻe moho no ka wehe ʻana i ka ʻokiʻoki piha (R0 resection).

ʻO ka pahuhopu o ka lapaʻau ʻaʻole wale ka wehe ʻana i ka maʻi maʻi akā e hōʻoiaʻiʻo ana i ke ola maʻi-ʻole (DFS) a me ke ola holoʻokoʻa (OS). ʻO ka neʻe ʻana i ka pre-operative systemic therapy ka manaʻo e hoʻohaʻahaʻa i ka ʻōpū, e maʻalahi a ʻoi aku ka maikaʻi o ke kaʻina.

ʻO ka hoʻololi ʻana mai Adjuvant i Neo-Adjuvant Therapy

No nā makahiki he mau makahiki, ʻo ka chemotherapy adjuvant (hāʻawi ʻia ma hope o ke ʻoki ʻana) ka mea maʻamau. ʻOiai hāʻawi ʻo ia i nā pōmaikaʻi liʻiliʻi, ʻaʻole pinepine ka hoʻokō ʻana ma muli o nā pilikia hoʻōla ma hope o ka ʻoki ʻana. ʻO ka neo-adjuvant therapy, i hāʻawi ʻia ma mua o ka hana ʻana, e hoʻoponopono i kēia ma ka mālama ʻana i ka mea maʻi ʻoiai lākou e kūpono ana.

Ua hōʻike ʻia nā hoʻokolohua lapaʻau hou i ka neo-adjuvant approaches e hāʻawi i nā helu pCR kiʻekiʻe ma mua o nā hoʻonohonoho adjuvant. ʻO ka loaʻa ʻana o ka pCR, kahi i waiho ʻole ʻia ai nā sela maʻi maʻi ola i loko o ke ʻano o ke kaʻina hana, pili ikaika ʻia me nā hopena lōʻihi i hoʻomaikaʻi ʻia. ʻO kēia hoʻololi paradigm ke kikowaena o ka ʻāina lapaʻau 2026.

Eia kekahi, ʻo ka neo-adjuvant therapy e hiki ai i nā kauka ke nānā i ka pane ʻana o ka tumor i ka manawa maoli. Inā ʻaʻole pane ka maʻi koko i ka regimen mua, hiki ke hoʻoponopono ʻia ka lāʻau ma mua o ka hana ʻana i ka ʻoki, pale i nā kaʻina hana ʻole i nā hihia maʻi koʻikoʻi.

ʻO 2026 ELCC nā holomua ma nā hoʻolālā Neo-Adjuvant

Ua lawelawe ʻia ka 2026 European Lung Cancer Congress (ELCC) ma ke ʻano he kahua koʻikoʻi no ka wehe ʻana i ka ʻikepili transformative i ka NSCLC reectable. Ua hoʻonohonoho kekahi mau haʻawina i hōʻike ʻia ma Copenhagen i nā hōʻailona hou no ka mālama maʻamau no ka Stage 2A a me nā maʻi holomua kūloko.

ʻO kekahi o nā kūkākūkā koʻikoʻi e pili ana i nā palena o ka iwi kuamoʻo "PD-1 inhibitor plus chemotherapy". ʻOiai ua hoʻokumu nā haʻawina e like me CheckMate 816 a me KEYNOTE-671 i kēia hui ʻana, ʻaʻole i loaʻa i kahi hapa nui o nā maʻi i ka pCR. Ke nānā nei ka noiʻi hou i ka hoʻoikaika ʻana i kēia mau regimen me ka palekana.

Ua hōʻike ka poʻe loea ma ELCC 2026 aia ka wā e hiki mai ana i nā hui pilikino. Hoʻopili kēia i ka hoʻohui ʻana i nā mea hou e like me nā antibodies bispecific a i ʻole ka hoʻohui ʻana i nā lāʻau lapaʻau kūloko e like me ka radiotherapy e hoʻoikaika i ka hoʻoulu ʻana o ka pale ma mua o ka pā ʻana o ka pahi i ka ʻili.

ʻO ka Neo-RISE Lung Study: He Paradigm Hou

ʻO kahi hōʻike kūʻokoʻa ma ELCC 2026 ka ʻikepili mua mai ka haʻawina ʻo Neo-RISE Lung. Ua ʻimi kēia hoʻāʻo hou i kahi ala ʻekolu-modality: immunogenic radiotherapy a ukali ʻia e kahi PD-1/VEGF bispecific antibody (ivonescimab) a me ka chemotherapy.

ʻO ke kumu o kēia hoʻolālā he synergistic. Hoʻoulu ka Radiotherapy i ka make ʻana o ka cell immunogenic, hoʻokuʻu i nā antigens tumor. Hoʻopaʻa ka antibody bispecific i ʻelua mau wahi hoʻopaʻa palekana i ka manawa like ʻoiai ke kāohi nei i ka angiogenesis ma o ka hoʻopau ʻana i ka VEGF. ʻO kēia "hoʻokahi-ʻelua punch" i ʻoi aku ka maikaʻi o ka ʻōnaehana pale ma mua o ka chemotherapy wale nō.

• Laki Pane Pahuhopu (ORR): Ua hōʻike ka haʻawina i kahi ORR maikaʻi o 100% i ka cohort loiloi.
• Pane Paʻa Paʻa (pCR): Ua hōʻea nā kumukūʻai i 55.1%, ʻoi aku ka kiʻekiʻe ma mua o nā mana mōʻaukala o ~24%.
• Pane Pathological Nui (MPR): Loaʻa i ka 79.3% o nā maʻi.
• Hoʻohaʻahaʻa: ʻO 88.2% o nā mea maʻi i ʻike i ka emi ʻana o ka maʻi maʻi, e hoʻomaʻamaʻa i ka wehe ʻana i ka ʻokiʻoki maʻalahi.

ʻO ka mea koʻikoʻi, ua loaʻa i nā maʻi āpau i hoʻomaka i ka ʻoki ʻana i ka R0 resection, ʻo ia hoʻi ʻaʻole i waiho ʻia nā maʻi kanesa ma nā ʻaoʻao. Hōʻike kēia ʻikepili no nā poʻe maʻi Stage 2A, hiki ke hoʻohui i ka radiotherapy a me nā mea ola ʻelua-targeting i mea maʻamau no nā hiʻohiʻona kiʻekiʻe.

KEYNOTE-671 ʻIke lōʻihi: Ka Mana o ka Immunotherapy Perioperative

ʻO kekahi pōhaku kihi o ka 2026 ELCC ʻo ia ka loiloi lōʻihi o ka hoʻāʻo ʻana o KEYNOTE-671. Ua loiloi kēia haʻawina Phase 3 i ka pembrolizumab i hui pū ʻia me ka chemotherapy ma ke ʻano he neo-adjuvant treatment, a ukali ʻia e adjuvant pembrolizumab monotherapy.

ʻO nā ʻike hou loa, e pili ana ma luna o 60 mau mahina o ka hahai ʻana, ua hōʻoia e paʻa ka pono o ka immunotherapy perioperative. ʻO ka mea nui, ua hoʻopili ka ʻikepili i nā mea maʻi e kā lākou pane pathological, e hāʻawi ana i nā ʻike nuanced no nā kauka lapaʻau e mālama ana i ka maʻi Stage 2A.

ʻO nā poʻe maʻi ʻaʻole i hoʻokō i kahi pane pathological piha (non-pCR) i loaʻa i nā pōmaikaʻi koʻikoʻi o ke ola ola ʻole (EFS). ʻO ka lākiō pōʻino no ka EFS ma ka hui non-pCR he 0.69, e hōʻike ana i ka hoʻemi ʻana o 31% i ka hopena o ka hoʻi hou ʻana a i ʻole ka make ma mua o kahi placebo.

No ka poʻe i hoʻokō i ka pCR, ʻokoʻa nā hopena, me ka helu EFS 5 makahiki o 81%. Hoʻoikaika kēia i ka manaʻo ʻoiai ʻo ka pCR kahi māka hoʻololi ikaika, ʻo ka hopena ʻōnaehana o ka immunotherapy e pale i nā maʻi me ka nānā ʻole i ka hohonu o ka pane pathological.

Nā lāʻau lapaʻau i manaʻo ʻia no ka maʻi maʻi maʻi maʻi maʻi 2A i hoʻololi ʻia i ke kaʻa

ʻAʻole i alakaʻi ʻia nā maʻi maʻi maʻi maʻi maʻi maʻi Stage 2A e nā ʻano hana like. Ma kahi o 15-20% o nā poʻe maʻi Komohana a hiki i ka 50% o nā maʻi maʻi ma Asia e hoʻololi i nā hoʻololi hoʻokele e like me EGFR a i ʻole ALK. No kēia mau kānaka, ʻaʻole paha ʻo ka immunotherapy wale nō ka hoʻolālā neo-adjuvant maikaʻi loa.

Hāʻawi ka 2026 ELCC i nā mea hou e pili ana i nā lāʻau lapaʻau i hoʻopaʻa ʻia i ka pae perioperative. Ua hoʻokumu mua ka hoʻokolokolo ADAURA i ka osimertinib ma ke ʻano he maʻamau no ka mālama adjuvant ma ka EGFR-mutated NSCLC. Ke koi nei nā ʻikepili hou i kēia mau mea hana i loko o ka neo-adjuvant space.

EGFR Mutations a me ka TOP Study Insights

ʻOiai ʻo ke aʻo ʻana ʻo TOP i kālele nui ʻia i ka maʻi metastatic kiʻekiʻe, ua hohonu kona hopena no ka mālama mua ʻana. Ua noiʻi ka haʻawina i ka osimertinib i hui pū ʻia me ka chemotherapy versus osimertinib wale nō i nā mea maʻi me nā hoʻololi EGFR a me nā hoʻololi like ʻana o TP53.

ʻIke ʻia nā co-mutations TP53 e hāʻawi i ke kūʻē ʻana i ka EGFR tyrosine kinase inhibitors (TKIs). Ua hōʻike ʻia ka haʻawina TOP ʻo ka hoʻohui ʻana i ka chemotherapy i ka osimertinib i pālua i ke ola holomua holomua (PFS) i loko o kēia pūʻulu kiʻekiʻe. Hōʻike kēia no nā maʻi maʻi Stage 2A me EGFR/TP53 co-mutations, pono paha kahi ala hoʻohui i ka hoʻonohonoho curative.

Ke hoʻopaʻapaʻa nei nā kānaka lapaʻau inā e hoʻohana i ka chemo-immunotherapy a i ʻole chemo-TKI hui pū ʻana no ka mālama neo-adjuvant i nā heluna kanaka hoʻokele. Ke neʻe nei ka ʻae ʻana i nā hoʻoholo i alakaʻi ʻia i ka molecularly ma mua o kahi ala immunotherapy hoʻokahi.

ʻO ka maʻi ALK Positive: ʻO ka hopena o ke aʻo ʻana o ALINA

No nā poʻe maʻi me ka hoʻoponopono hou ʻana o ALK, ʻo ka haʻawina ALINA he mea hoʻololi pāʻani. Ua hōʻike ʻia ka hoʻomaikaʻi nui ʻana o ka adjuvant alectinib i ka DFS i hoʻohālikelike ʻia me ka platinum-based chemotherapy. ʻOiai ʻoi aku ka liʻiliʻi o ka ʻikepili neo-adjuvant ma mua o ka ʻikepili adjuvant, ke noiʻi ikaika ʻia nei ka maikaʻi o ka alectinib i ka hōʻemi ʻana i nā maʻi maʻi ma mua.

I ka makahiki 2026, aia ka manaʻo i ka hoʻoholo ʻana i ka lōʻihi o ka lōʻihi o ka lāʻau lapaʻau. Pono e hāʻawi wale ʻia ma hope o ka ʻoki ʻana, a i ʻole e hoʻohana ʻia kahi ala "sandwich" (neo-adjuvant + adjuvant)? Hōʻike nā hōʻailona mua e hiki ke hoʻomaʻamaʻa i ka lāʻau lapaʻau i hoʻopaʻa ʻia ma mua o ka hana ʻana i nā ʻokiʻoki liʻiliʻi, e mālama ana i ka hana o ka māmā i nā maʻi maʻi Stage 2A.

Hoʻohālikelike Hoʻohālikelike o nā ʻano Lapaʻau

Ke koho ʻana i ka pono pae 2a ka mālama ʻana i ka maʻi kanesa pono e kaupaona i nā pono a me nā pilikia o nā ʻano hana like ʻole. Hoʻohālikelike ka papa ma lalo i nā hoʻolālā alakaʻi i kūkākūkā ʻia ma ELCC 2026.

Hōʻike kēia hoʻohālikelike "ʻaʻole kūpono ka nui hoʻokahi." ʻO ka loaʻa ʻana o nā hōʻailona genetic kikoʻī a i ʻole ka nui o ka ʻōpū e hiki ke kuhikuhi inā loaʻa ka pōmaikaʻi o ka mea maʻi mai ka chemo-immunotherapy maʻamau, kahi hoʻokolohua hoʻoikaika ʻia, a i ʻole nā ​​​​mea i koho ʻia.

ʻO nā pono a me nā pōʻino o nā Neo-Adjuvant approaches

ʻO ka hoʻohana ʻana i ka lāʻau neo-adjuvant no ka Stage 2A ka maʻi maʻi ʻaʻai māmā e hāʻawi i nā pono kūʻokoʻa akā hoʻolauna pū kekahi i nā luʻi hou e pono ai nā hui multidisciplinary e hoʻokele.

• Pono:
  • Ka hoʻomalu ʻōnaehana mua: Hoʻomaʻamaʻa koke i nā micrometastases, e hōʻemi ana i ka hopena o ka hoʻi hou ʻana.
  • I ka hoʻāʻo ʻana i ka Vivo Sensitivity: Hāʻawi i nā kauka e ʻike inā e emi ana ke koko, e hāʻawi ana i ka ʻike prognostic.
  • Hoʻomaikaʻi i ka Resectability: Hiki ke hoʻohaʻahaʻa i nā maʻi maʻi, e hoʻololi i nā hihia hiki ke hoʻopau ʻia i ka palena e hoʻomaʻemaʻe i nā resections R0.
  • Hoʻokō kiʻekiʻe: ʻOi aku ka maikaʻi o ka poʻe maʻi i ka ʻōnaehana systemic ma mua o ka wā o ka hoʻihoʻi ʻana.
• Nā hemahema:
  • Hoʻopaneʻe i ka ʻoki ʻana: Hana ʻia ka mālama ʻana i nā hebedoma, hiki ke hōʻeha i ka hopohopo a i ʻole ka holomua ʻana i nā hihia koʻikoʻi.
  • Paʻakikī o ke kaʻina hana: ʻO ka maʻi a i ʻole ka fibrosis i hoʻokumu ʻia e ka lāʻau lapaʻau hiki i kekahi manawa ke paʻakikī i ka wehe ʻana i nā kauka.
  • ʻO nā pilikia ʻona: Hiki i nā hanana ʻino (irAEs) pili i ke kino ke hana ma mua o ka hana ʻana, hiki ke hoʻopili i ka anesthesia a i ʻole ka ho'ōla ʻana i ka ʻeha.

ʻOiai kēia mau paʻakikī, kākoʻo nā hōʻike nui mai 2026 i ka pono ʻupena o nā hoʻolālā neo-adjuvant no nā maʻi maʻi Stage 2A. Aia ke kī i ke koho maʻi maʻi a me ka hoʻonohonoho multidisciplinary ikaika.

Alakaʻi ʻanuʻu i ka hoʻokele 2A o kēia wā

ʻO ka hoʻokele ʻana i ka huakaʻi lapaʻau no ka Stage 2A maʻi maʻi maʻi maʻi i ka makahiki 2026 e pili ana i kahi kaʻina hana multidisciplinary. Eia kahi kaʻina hana maʻamau e pili ana i nā hana maikaʻi loa o kēia manawa.

• KaʻAnuʻu Hana 1: Hoʻokumu piha a me ka Molecular Profiling
  
  Ma mua o ka hoʻoholo ʻana i ka lāʻau lapaʻau, e hoʻopaʻa ʻia nā mea maʻi i ka PET-CT scans a me ka lolo MRI e hoʻoholo i ka metastasis mamao. ʻO ka mea koʻikoʻi, pono e hoʻāʻo ʻia ka biopsy kiko no ka EGFR, ALK, ROS1, a me ka ʻōlelo PD-L1. Hoʻoholo kēia ʻanuʻu inā komo ka mea maʻi i ka immunotherapy a i ʻole ke ala lapaʻau i kuhikuhi ʻia.
• KaʻAnuʻu 2: Hōʻike Manaʻo Hui Pūʻulu Multidisciplinary (MDT).
  
  ʻO kahi hui e hui pū ana i nā kauka ʻokiʻoki, nā mea lapaʻau oncologists, radiation oncologists, a me nā pathologists e loiloi i ka hihia. Nānā lākou i ka resctability a kūkākūkā i nā pono kūpono o ka neo-adjuvant therapy versus upfront surgery e pili ana i ka ʻikepili ELCC hou loa.
• KaʻAnuʻu 3: Hoʻomaka i ka Neo-Adjuvant Therapy
  
  Inā kūpono, hoʻomaka ka mea maʻi i ka regimen i koho ʻia. No nā poʻe maʻi hoʻokele-ʻino, ʻo kēia ka mea maʻamau he 3-4 mau pōʻai o ka platinum-doublet chemotherapy me kahi mea paʻa PD-1/PD-L1. No nā hihia koʻikoʻi, hiki ke hāʻawi ʻia nā hoʻokolohua lapaʻau e pili ana i nā antibodies bispecific a i ʻole radiotherapy.
• KaʻAnuʻu Hana 4: Hoʻomaka hou a me ka hoʻolālā ʻana
  
  Ma hope o ka pau ʻana o nā neo-adjuvant cycles, hana hou ʻia ke kiʻi no ka loiloi i ka pane. Inā paʻa a pane mai paha ka maʻi, hoʻonohonoho maʻamau ʻia ke ʻoki ʻana he 3-6 mau pule ma hope o ka hopena hope loa o ka immunotherapy e ʻae ai i ka hoʻihoʻi ʻana.
• KaʻAnuʻu Hana 5: ʻoki ʻokiʻoki a me ka loiloi pathological
  
  Hana ke kauka lapaʻau i kahi lobectomy a i ʻole segmentectomy me ka wehe ʻana o ka lymph node. Nānā ka mea hoʻoponopono i ka specimen no ka hoʻoholo ʻana i ka Major Pathological Response (MPR) a i ʻole Pathological Complete Response (pCR), nāna e alakaʻi i ka mālama hou aku.
• KaʻAnuʻu Hana 6: Adjuvant Consolidation
  
  Ma muli o ka hoʻolālā mua a me nā ʻike pathological, hiki i nā maʻi ke hoʻomau i ka adjuvant immunotherapy (e laʻa, pembrolizumab) a hiki i hoʻokahi makahiki a i ʻole e hoʻololi i ka lāʻau lapaʻau i manaʻo ʻia (e laʻa, osimertinib) inā loaʻa kahi hoʻololi. ʻO kēia ala "perioperative" e hōʻoia i ka pale mau ʻana mai ka hoʻi hou ʻana.

ʻO ke kuleana o ka maʻi koena liʻiliʻi (MRD).

ʻO kahi mea hana e kū mai ana i ka makahiki 2026 ka hoʻohana ʻana i ka DNA tumor circulating (ctDNA) e nānā i ka Minimal Residual Disease (MRD). ʻIke kēia ʻenehana i nā helu liʻiliʻi o ka DNA maʻi maʻi i loko o ke koko i ʻike ʻole ʻia e ke kiʻi.

Hōʻike nā haʻawina i hōʻike ʻia ma nā ʻaha kūkā i hala aku nei ʻo ka hoʻomaʻemaʻe ʻana i ka ctDNA i ka wā neo-adjuvant therapy he mea wānana ikaika no ke ola lōʻihi. ʻO ka mea ʻē aʻe, ʻo ka ctDNA hoʻomau ma hope o ke kaʻina ʻana hiki ke ʻike i nā maʻi e pono ai ka piʻi ʻana o ka lāʻau adjuvant. ʻOiai ʻaʻole i koi ʻia ma ke ao holoʻokoʻa, ua lilo ka nānā ʻana i ka MRD i mea maʻamau o ka oncology precision no ka maʻi maʻi maʻi maʻi maʻi Stage 2A.

No ka laʻana, ua hōʻike ka ʻikepili ma ka cadonilimab (he PD-1/CTLA-4 bispecific antibody) i ka poʻe maʻi i loaʻa i ka ʻae ctDNA ua ʻoi aku ka lōʻihi o ke ola holomua ʻole. Hāʻawi kēia molecular feedback loop no ka hoʻoponopono ʻana i ka mālama ʻana, ka neʻe ʻana mai nā protocol lōʻihi paʻa.

Nā Noʻonoʻo Hoʻomaʻamaʻa no nā Lehulehu Kūikawā

ʻAʻole kūlike ka mālama ʻana i ka maʻi maʻi maʻi maʻi maʻi maʻi pae 2A ma nā ʻano demographic āpau. Pono nā kānaka kiko'ī i nā ala kūpono e kaulike i ka pono me ka palekana.

ʻO nā maʻi ʻelemakule a me nā poʻe me ke kūlana hana maikaʻi ʻole

ʻO ka poʻe ʻelemakule a i ʻole nā ​​maʻi me nā maʻi maʻi e hakakā pinepine nei me ka ʻona o ka chemo-immunotherapy piha. Ua ʻimi ka hoʻāʻo ʻo ETOP ADEPPT a me nā haʻawina like i nā hoʻoponopono hoʻohaʻahaʻa a i ʻole nā ​​mea lapaʻau i hoʻopaʻa ʻia no kēia mau pūʻulu.

I ka makahiki 2026, ke hele nei ke ʻano i ka "de-escalation" no nā maʻi palupalu. Hiki paha i kēia ke hoʻohana i ka monotherapy immunotherapy inā kiʻekiʻe ka ʻōlelo PD-L1, a i ʻole ke koho ʻana i nā ʻelele i hoʻopaʻa ʻia inā loaʻa kahi hoʻololi o ke kaʻa, e pale aku i nā hopena ʻino o ka platinum chemotherapy. Hoʻomaʻa mau ka pahuhopu, akā hoʻoponopono ʻia ke ala e hōʻoia i ka mea maʻi hiki ke hoʻopau i ka mālama ʻana.

ʻO nā maʻi me nā Metastases Brain

ʻOiai ʻo ka Stage 2A ʻaʻole ia e hoʻolaha mamao, hiki ke ʻike ʻia nā metastases lolo occult i kekahi manawa ma ka nānā kikoʻī. ʻO nā TKI o nā hanauna hou e like me ka osimertinib a me ka alectinib he mea maikaʻi loa ke komo ʻana o ka ʻōnaehana nerve waena (CNS).

No nā poʻe maʻi me nā metastases lolo liʻiliʻi i ʻike ʻia i ka wā o ka hoʻokele ʻana, ʻo ka hoʻomaʻamaʻa ʻōnaehana me nā lāʻau CNS-active ka mea ma mua o ka mālama ʻana i ka lolo kūloko. Ua hoʻoikaika nā haʻawina ARTS a me ALINA i ka hilinaʻi i ka mālama ʻana i nā maʻi o ka wā mua me nā mea hana e pale ai i ka lolo, e hōʻemi ana i ka pono o ka hoʻoheheʻe cranial invasive i kekahi mau hihia.

Nā kuhikuhi e hiki mai ana a me ka noiʻi mau ʻana

ʻO ka ʻāina o pae 2a ka mālama ʻana i ka maʻi kanesa he dynamic. Ke neʻe nei mākou i 2026, ua hoʻohiki kekahi mau wahi o ka noiʻi e hoʻomaikaʻi hou i nā hopena. ʻO ka hoʻohui ʻana o ka naʻauao artificial i ka radiomics ke kōkua nei i ka wānana i nā mea maʻi e pane i ka neo-adjuvant therapy ma mua o ka hoʻomaka ʻana o ka mālama ʻana.

Hoʻohui hou, ke wehe nei ka hoʻomohala ʻana o nā antibody-drug conjugates (ADCs) i nā puka hou. ʻO nā hoʻāʻo e pili ana i nā ADC i alakaʻi ʻia e HER3 a me TROP2-targeted agents e hōʻike ana i ka ʻōlelo hoʻohiki i ka neo-adjuvant hoʻonohonoho, hiki ke hāʻawi i nā koho no nā maʻi i pane ʻole i ka immunotherapy maʻamau.

ʻO ka manaʻo o ka "total neoadjuvant therapy" ke loaʻa pū nei ka traction. Hoʻopau loa kēia ala i ka adjuvant therapy, e hāʻawi ana i nā lāʻau ʻōnaehana āpau ma mua o ke ʻoki ʻana. Hōʻike ka ʻikepili mua e hiki ke maʻalahi i ka huakaʻi maʻi a hoʻomaikaʻi i ka hoʻokō ʻana, ʻoiai ke oʻo nei ka ʻikepili ola lōʻihi.

ʻO ke koʻikoʻi o nā hoʻokolohua lapaʻau

Hāʻawi ʻia i ka loli wikiwiki o nā kūlana lapaʻau, paipai nui ʻia ke kākau inoa ʻana i nā hoʻokolohua lapaʻau no nā maʻi maʻi Stage 2A. ʻO nā hoʻāʻo e like me Galaxy-L-01, ka noiʻi ʻana i ka garsorasib i hui pū ʻia me ka anlotinib no nā hoʻololi KRAS G12C, hāʻawi i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki ma mua o ka loaʻa ʻana o ka nui.

ʻO ke komo ʻana i kēia mau haʻawina ʻaʻole wale ka pōmaikaʻi i ka mea maʻi hoʻokahi akā hāʻawi pū kekahi i ka waihona ʻike honua, e wikiwiki ana i ka loaʻa ʻana o nā lāʻau lapaʻau. Paipai ʻia nā kauka e kūkākūkā i ka pono o ka hoʻokolokolo me kēlā me kēia maʻi kūpono i ka maʻi maʻi.

Ka Hopena: He Au Hou o ka Manaolana no ka Papa 2A Ka ma'i ma'i 'a'ai

Hōʻike ka makahiki 2026 i kahi hoʻololi paʻa i ka hoʻokele ʻana o ka Stage 2A non-small cell lung cancer. Ua hala nā lā i hoʻokahi wale nō pane. I kēia lā, pae 2a ka mālama ʻana i ka maʻi kanesa He hana maʻalahi, multimodal e hui pū ana i ka pololei o ka lāʻau lapaʻau i manaʻo ʻia, ka mana o ka immunotherapy, a me ka manawa hoʻolālā o ka neo-adjuvant interventions.

Hōʻike ka ʻikepili mai ka 2026 ELCC, e pili ana i ka noiʻi ʻana o Neo-RISE Lung a me nā hopena KEYNOTE-671 lōʻihi, hiki iā mākou ke hoʻokō i nā helu hoʻōla kiʻekiʻe ma mua o ka wā ma mua. Ma ka hoʻopilikino ʻana i ka mālama ʻana e pili ana i nā molecular profiles a me ka hoʻohana ʻana i nā hui hou e like me nā antibodies bispecific a me ka radiotherapy immunogenic, ke hoʻohuli nei nā kauka i nā hihia paʻakikī i nā moʻolelo kūleʻa.

No nā poʻe maʻi a me nā ʻohana, ʻo ia ke ʻano o ka wā e hiki mai ana me nā koho hou aku, ʻoi aku ka maikaʻi o ke ola ʻana, a me ka maikaʻi o ke ola. Ke hoʻomau nei ka noiʻi e wehe i nā paʻakikī o ka biology maʻi maʻi ʻāʻī, kuhikuhi ka trajectory i nā ala ʻoi aku ka maikaʻi, ʻoi aku ka ʻona, a me nā ala mālama pilikino. ʻO ka hui pū ʻana ma waena o nā kauka lapaʻau, oncologists, a me nā mea noiʻi e noho mau ana i ka pōhaku kihi o kēia holomua, e hōʻoia ana e loaʻa i kēlā me kēia maʻi Stage 2A ka manawa kūpono loa i kahi lāʻau.